3 TSX Stocks Under $20 That Could Double Your Money

These three stocks, which currently trades below $20, are perfectly positioned to double your investments in the next three years.

| More on:
Canadian Dollars

Image source: Getty Images

You don’t need a considerable amount of money to start investing in the stock market. Even with small but regular investments, you can build a decent capital for your future. In this article, we will look at three stocks that are currently trading under $20 but can double in over the next three years.

Absolute Software

My first pick is Absolute Software (TSX:ABT), which provides management and security solutions through a SaaS (software-as-a-solution) business model. The company’s stock is up by over 80% this year. Earlier this week, the company had reported an impressive fourth-quarter performance outperforming analysts’ expectations.

Year-over-year, its revenue grew 7% to US$27.2 million, while its adjusted EBITDA rose over 60% to US$8 million. Its total annual recurring revenue, the indicator of the company’s future recurring revenue, grew by 11% during the quarter. The strong performance from its enterprise and government segments drove its revenue.

For fiscal 2021, Absolute Software’s management expects its revenue to grow in the range of 7%-13%, while its adjusted EBITDA margin to come in between 20%-24%. The demand for Absolute Software’s products and services has increased, as many people have started working from their homes, increasing the chances of data breaches and cyber-attacks.

Meanwhile, with many companies warming up to the idea of remote working, I believe the demand for Absolute Software’s products and services could rise further. Thus, I am bullish on the stock. I expect the company’s stock price to double in the next two to three years.

Aurora Cannabis

My second pick is Aurora Cannabis (TSX:ACB)(NYSE:ACB). It has lost close to 60% of its stock value this year. However, the company’s long-term growth prospects remain intact. In February, the company had launched its value brand, Daily Special, which has received a good response from the customers. It also helped the company in increasing its market share.

In May, Aurora Cannabis entered the United States CBD market by acquiring Reliva for US$40 million. With BDS Analytics projecting the CBD market in the United States to reach US$20 billion by 2024, this acquisition provides substantial growth potential.

Meanwhile, the company’s management has set a target to report positive EBITDA by the first quarter of fiscal 2021. The company has managed to bring its cash cost to produce one gram of cannabis down to $0.85.

Further, the management has announced several cost-cutting initiatives to lower its selling, general, and administrative expenses. All these initiatives could improve the company’s margins. So, I firmly believe Aurora Cannabis’s stock price could easily double from its current levels in the next three years.

Kinross Gold

My third pick is Kinross Gold (TSX:K)(NYSE:KGC), which mines for gold and silver. Currently, it has returned close to 90% for this year. The surge in gold prices and an impressive second-quarter performance drove the company’s stock price.

So far, gold prices have increased by over 50% this year. However, many industry experts are expecting gold prices to rise even further. As reported by CNBC on August 10, Frank Holmes, CEO of U.S. Global Investors, expects gold prices to hit US$4,000 per ounce in the next three years, given the stimulus packages announced by various central banks across the world.

Besides the surge in gold prices, the increased production from its three low-cost mines could boost Kinross Gold’s margins. So, I believe the company’s stock price would continue to rise.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. 

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »